Endothelin Receptor Antagonism in Proteinuric Nephropathy

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2007

Conditions
Chronic Kidney DiseaseProteinuria
Interventions
DRUG

BQ-123 (selective endothelin A receptor antagonist)

Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.

DRUG

0.9 % saline

Single 15ml 0.9% saline infused for 15 mins as placebo control

DRUG

Nifedipine

Single dose of nifedipine 10 mg given orally as active control

Trial Locations (1)

EH4 2XU

Clinical Research Centre, Western General Hospital, Edinburgh

All Listed Sponsors
collaborator

British Heart Foundation

OTHER

lead

University of Edinburgh

OTHER

NCT00722215 - Endothelin Receptor Antagonism in Proteinuric Nephropathy | Biotech Hunter | Biotech Hunter